10 Cheapest Stocks Insiders Are Buying Recently

6. Regulus Therapeutics Inc. (NASDAQ:RGLS)

Average price per share: $1.08

Market capitalization: $85.15 million

The sixth stock among these cheapest penny stocks insiders have been purchasing is a biopharmaceutical company engaged in the discovery and development of innovative medicines targeting microRNAs. Among the company’s leading candidates is Farabursen (RGLS8429), an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. The San Diego, California-headquartered company is also working on a pipeline of preclinical drug products for target organ-selective delivery strategies.

On January 29, the company announced positive clinical and regulatory updates from its autosomal dominant polycystic kidney disease program for Farabursen. “The results from Cohort 4 are very promising, further validating the impact of farabursen on urinary exosomal polycystin levels and suggesting an opportunity to beneficially impact kidney volume growth rate, as we have now observed notable improvements across multiple treatment cohorts,” stated Alan Yu, M.D., University of Kansas Medical Center.

Following the news, on January 30, two insiders acquired a total of around $75,046 worth of Regulus Therapeutics shares at an average price of $1.08 per share. Out of the total amount, the company’s CEO, P Joseph Hagan, bought 50,000 shares, increasing his ownership to 260,808 shares. The stock is now trading at $1.30 per share, as it lost 17.72% since the beginning of the year. Over the past 12 months, Regulus Therapeutics shares dropped 16.13%.

Regulus Therapeutics has an average “Strong Buy” rating from six analysts. Data from StockAnalysis further reveals a 12-month price forecast is $10.33, representing an increase of 694.62% from the previous price.